TG THERAPEUTICS INC (TGTX)

US88322Q1085 - Common Stock

8.77  -0.05 (-0.57%)

After market: 8.76 -0.01 (-0.11%)

TG THERAPEUTICS INC

NASDAQ:TGTX (9/28/2023, 7:16:40 PM)

After market: 8.76 -0.01 (-0.11%)

8.77

-0.05 (-0.57%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-01 2023-08-01/bmo
Earnings (Next)11-08 2023-11-08/bmo
Ins Owners8.78%
Inst Owners58.67%
Market Cap1.32B
Shares150.98M
PEN/A
Fwd PE171.96
Dividend YieldN/A
Analysts80
IPO12-14 1995-12-14
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

TGTX Daily chart

Company Profile

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 244 full-time employees. The firm is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. The company evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Company Info

TG THERAPEUTICS INC

2 Gansevoort Street, 9Th Floor

New York City NEW YORK 10014

P: 12125544484.0

CEO: Michael S. Weiss

Employees: 244

Website: https://www.tgtherapeutics.com/

TGTX News

News Image11 hours ago - Market News VideoInteresting TGTX Put And Call Options For November 10th
News Image7 days ago - TG Therapeutics, Inc.TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET...

News Image15 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX). Such...

News Image22 days ago - TG Therapeutics, Inc.TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Fireside chat scheduled for Monday, September 11, 2023, at 10:30 AM ET...

News Imagea month ago - InvestorPlace3 Very Oversold Biotech Stocks to Buy Right Now

These biotech stocks have tumbled a great deal in recent months, but their long-term outlooks remain quite strong. 

News Image2 months ago - Market News VideoTop Buys by Directors: Weiss's $1M Bet on TGTX

TGTX Twits

Here you can normally see the latest stock twits on TGTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example